Management & Directors

Management

Richard A. Sandberg

Co-Chairman of the Board of Directors and CEO, Mr. Sandberg has played a principal role in starting and building a number of biotech companies including that of founder, chairman, chief executive officer, and chief financial officer of DIANON Systems Inc., a publicly traded oncology diagnostics company that was a pioneer in marketing new diagnostic technologies as a service rather than a product offering. He also served as chairman and chief financial officer of Lifecodes Corporation, a pioneer in DNA testing technology, and chief financial officer and director of Matritech, Inc., a publicly traded biotechnology company specializing in proteomic diagnostic products for the early detection of a variety of cancers.

He currently serves as a director of Oxford Immunotec Global, plc., a publicly traded diagnostic company focused on chronic diseases like tuberculosis, Lyme Disease, and cytomegalovirus. From 2005 to 2009, he served as a director of North American Scientific Inc., a publicly held developer and marketer of radiation therapy products and systems for treating breast and prostate cancer, and from 2003 to 2009 as a director of Ethan Allen Interiors Inc., an international manufacturer and retailer of fine home furnishings. He has served as a director of a number of private healthcare companies in fields such as pharmaceuticals, point of care diagnostics and cancer screening.

John McMichael, Ph.D.

Co-Chairman of the Board of Directors and President, Dr. McMichael has over two decades of experience as a founder and executive of start-up companies including Molecular Rx, Inc.; ImmunoTherapeutics, Inc; Milkhaus Laboratory, Inc.; and Beech Tree Labs, Inc. He is also the Founder and President of The Institute for Therapeutic Discovery, a not-for-profit organization focused on bridging biochemistry and biophysics. An Alzheimer’s disease research pioneer, Dr. McMichael licensed over 30 Alzheimer’s patents to Élan Corp, plc., and has more than 100 patents to his credit.

From 1975 through 1986, Dr. McMichael served on the faculty of Edinboro University in various positions culminating as Professor, Biology and Health Sciences. His other academic appointments include the Wistar Institute (1973-74) and SUNY-Cobleskill (1988 to the present). He received his Ph.D. from Oregon State University in immunology and virology where his doctoral work involved developing the world’s first live-virus vaccines for fish which led to changing industry-wide standards to help prevent fish hatchery losses.

Thomas Hatch

Executive Vice President, Mr. Hatch is an experienced business leader in the animal health industry. He joined the predecessor company to Beech Tree Labs in 2002 as the President of its wholly-owned veterinary products subsidiary. He previously served as President and CEO of Immucell Corporation, a publicly traded animal health company, and as General Manager of Operations for Neogen Corporation. Mr. Hatch is a graduate of the Darden School of Business, University of Virginia.

Board of Directors

James R. Tobin

Appointed to the Board in August 2017, Mr. Tobin served as chief executive officer and president of Boston Scientific Corporation, a medical device company from March 1999 to July 2009. Prior to that, he served as the chief executive officer and president of Biogen Idec, Inc., or Biogen, a global biotech company, and from 1994 to 1997 as Biogen’s president and chief operating officer. Before joining Biogen, Mr. Tobin spent 22 years with Baxter International, Inc. a global healthcare company, rising from financial analyst to president and chief operating officer during his tenure. He is currently a member of the board of directors of Globus Medical, Inc., a publicly traded medical device company; Oxford Immunotec, Ltd, a publicly traded diagnostic company; and two other private companies. Mr. Tobin is a graduate of Harvard College and Harvard Business School. He served as a Lieutenant in the U.S. Navy from 1968 to 1972.

Damian Marron

Appointed to the Board in March 2018, Mr. Marron is an experienced life sciences executive with a successful track record leading public and private biotechnology companies. He served as CEO and Director of Agalimmune Ltd, a late pre-clinical stage, semi-virtual, immune-oncology company with a highly innovative anti-cancer immunotherapy technology. During this time, Mr. Marron completed the acquisition of Agalimmune by BioLineRx, a Nasdaq listed, Israeli clinical-stage biotech. Prior to this, he was CEO and Director of TxCell SA, France, a T-cell immunotherapy company, where he had a successful IPO for the company on NYSE Euronext. Mr. Marron was also CEO and Director of Cytheris SA, France, where he refocused the company’s strategy on an orphan indication, and later sold the company’s main asset for several million Euros. Furthermore, he was CEO and Director of Trophos SA, France, where he positioned Trophos as an orphan neurology drug company, and designed and implemented the strategy leading to its subsequent acquisition by Roche.

Mr. Marron is currently a non-Executive Director at Bone Therapeutics, a clinical stage, regenerative medicine company listed on Euronext, and Agalimmune, an immune-oncology subsidiary of BioLine Rx, and Senior Advisor with Treehill Partners, a global healthcare advisory boutique. He holds a BSc (Hons) in Pharmacology from the University of Liverpool.

Jeffrey A. Eckmann

A member of the Board of Directors of Beech Tree Labs, Inc. and Emergency MCG USA, Inc., Mr. Eckmann previously served as Group President for Reynolds American, Inc., where he managed four of their five business units as well as corporate strategy, corporate development and mergers and acquisitions. Previously, he was Senior Vice President and Chief Financial Officer for Brown & Williamson Tobacco Corporation, having led the integration of the 2004, $4.5 billion merger between R.J. Reynolds and Brown & Williamson. Mr. Eckmann began his career with Price Waterhouse. He currently serves on the board of Alliance One International and chairs its audit committee. Mr. Eckmann is a graduate of the Harvard Business School Advanced Management Program.

Richard A. Sandberg

Please see Management

John McMichael, Ph.D.

Please see Management

Thomas Hatch

Please see Management